Novel therapies are changing treatment paradigms in metastatic prostate cancer
Metastatic castration-resistant prostate cancer (mCRPC) remains a terminal diagnosis with
an aggressive disease course despite currently approved therapeutics. The recent …
an aggressive disease course despite currently approved therapeutics. The recent …
Treating prostate cancer by antibody–drug conjugates
M Rosellini, M Santoni, V Mollica, A Rizzo… - International journal of …, 2021 - mdpi.com
Prostate cancer is the most frequent malignancy in the worldwide male population; it is also
one of the most common among all the leading cancer-related death causes. In the last two …
one of the most common among all the leading cancer-related death causes. In the last two …
Phase I study of cabozantinib and nivolumab alone or with ipilimumab for advanced or metastatic urothelial carcinoma and other genitourinary tumors
PURPOSE We assessed the safety and efficacy of cabozantinib and nivolumab (CaboNivo)
and CaboNivo plus ipilimumab (CaboNivoIpi) in patients with metastatic urothelial …
and CaboNivo plus ipilimumab (CaboNivoIpi) in patients with metastatic urothelial …
Treatment landscape for patients with castration-resistant prostate cancer: patient selection and unmet clinical needs
F Turco, S Gillessen, R Cathomas… - Research and reports …, 2022 - Taylor & Francis
Metastatic castration resistant prostate cancer (CRPC) is an inevitably fatal disease.
However, in recent years, several treatments have been shown to improve the outcome of …
However, in recent years, several treatments have been shown to improve the outcome of …
Apalutamide, enzalutamide, and darolutamide for non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis
Management of non-metastatic castration-resistant prostate cancer (nmCRPC) has
undergone a paradigm shift with next-generation androgen receptor inhibitors. However …
undergone a paradigm shift with next-generation androgen receptor inhibitors. However …
Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate …
Background The most recent overall survival (OS) and adverse event (AE) data have not
been compared for the three guideline-recommended high-risk non-metastatic castration …
been compared for the three guideline-recommended high-risk non-metastatic castration …
[HTML][HTML] Final results of a randomized, placebo-controlled, two-arm, parallel clinical trial of proxalutamide for hospitalized COVID-19 patients: a multiregional, joint …
FA Cadegiani, RA Zimerman, DN Fonseca, MN Correia… - Cureus, 2021 - ncbi.nlm.nih.gov
Background The role of androgens on COVID-19 is well established. Proxalutamide is a
second-generation, non-steroidal antiandrogen (NSAA) with the highest antiandrogen …
second-generation, non-steroidal antiandrogen (NSAA) with the highest antiandrogen …
Current status and future perspectives of androgen receptor inhibition therapy for prostate cancer: a comprehensive review
TJ Kim, YH Lee, KC Koo - Biomolecules, 2021 - mdpi.com
The androgen receptor (AR) is one of the main components in the development and
progression of prostate cancer (PCa), and treatment strategies are mostly directed toward …
progression of prostate cancer (PCa), and treatment strategies are mostly directed toward …
Efficacy and safety of androgen receptor inhibitors for treatment of advanced prostate cancer: A systematic review and network meta‐analysis
S Xiao, H Yin, X Lv, Z Wang, L Jiang… - British Journal of …, 2024 - Wiley Online Library
Aims Androgen receptor inhibitors (ARIs) have become an effective treatment for advanced
prostate cancer (PC). However, it is unknown which ARI is the most helpful and safe for men …
prostate cancer (PC). However, it is unknown which ARI is the most helpful and safe for men …
Comparison of treatments for nonmetastatic castration-resistant prostate cancer: matching-adjusted indirect comparison and network meta-analysis
L Wang, C Paller, H Hong, L Rosman… - JNCI: Journal of the …, 2022 - academic.oup.com
Background For nonmetastatic castration-resistant prostate cancer (nmCRPC), 3 drugs
under patent protection—apalutamide, enzalutamide, and darolutamide—were approved …
under patent protection—apalutamide, enzalutamide, and darolutamide—were approved …